Prognostic Value of Lymph Node Necrosis at Different N Stages in Patients with Nasopharyngeal Carcinoma
Yue-Chun Fu,Shao-Bo Liang,Wen-Jie Huang,Lu-Si Chen,Dan-Ming Chen,Li-Zhi Liu,Min Luo,Xiao-Fen Zhong,Xiang-Ying Xu
DOI: https://doi.org/10.7150/jca.84854
IF: 3.9
2023-01-01
Journal of Cancer
Abstract:<b>Background:</b> Lymph node necrosis (LNN), including retropharyngeal nodal necrosis and cervical nodal necrosis, which is related to radiotherapy/ chemotherapy resistance, is a common phenomenon in nasopharyngeal carcinoma (NPC). This study was to assess the prognostic value of LNN at different N stages in NPC patients. <b>Materials and Methods:</b> In total, 1,665 newly diagnosed NPC patients at stage TxN1-3M0 from two centers were enrolled. Univariate and multivariate models were constructed to assess the association between LNN and long-term survival outcomes. The propensity score matching method was performed to balance treatment groups for baseline characteristics. <b>Results:</b> Of the 1,665, 540 patients (540/1665, 32.4%) were diagnosed with LNN, of which 54.1% (292/540) patients were at stage N1, 31.3% (169/540) at stage N2, and 14.6% (79/540) at stage N3. Univariate and multivariate analyses indicated LNN as an independent predictor for progression‑free survival (PFS), overall survival (OS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) in stage N1-3 patients (all <i>P</i><0.001). When patients were analyzed according to stage, similar findings were observed for N1 patients (all <i>P</i><0.001); for N2 patients, LNN independently predicted PFS (<i>P</i>=0.003), OS (<i>P</i>=0.011), and DMFS (<i>P</i>=0.004), and for stage N3, LNN only independently predicted LRRFS (<i>P</i>=0.019). 123 pairs of patients who received induction chemotherapy plus concurrent chemoradiotherapy or only concurrent chemoradiotherapy were matched, adding induction chemotherapy improved 5-year OS, PFS and LRFFS, but the results were not statistically significant. <b>Conclusions:</b> In NPC patients, LNN could independently predict poor prognosis at all N1-3 stages and at each N stage (N1 to N3). The value of adding induction chemotherapy to concurrent chemoradiotherapy in patients with LNN still requires further prospective studies.
oncology